A New Strategy of Drug Treatment in NSAID-Unresponsive Ankylosing Spondylitis: Combination of Pamidronate and Methylprednisolone Monthly Intravenous Infusions on The Background of A Combination of Disease Modifying Drugs Sulfasalazine and Methotrexate

AN Malaviya*, S Kapoor**, S Garg**, I Ahmad***, RR Raja****

Abstract

Objectives: To assess short term efficacy and tolerability of a therapeutic strategy in patients with ankylosing spondylitis (AS) unresponsive to nonsteroidal anti-inflammatory drugs (NSAIDs) or coxibs and unable to take anti-tumour necrosis factor-α (anti-TNFα) biological treatment.

Methods: Established AS patients were given a background treatment consisting of subcutaneous injections of methotrexate weekly (MTX, dose stepped up to a maximum of 20 to 25 mg), weekly 12-16 mg of methylprednisolone orally 30 mts before methotrexate dose (for nausea prevention), sulfasalazine (SSZ, 1 gm orally twice per day) with folic acid supplementation (5 mg daily except on the day of MTX). Additionally, they were given monthly cycles of intravenous (IV) methylprednisolone ‘pulse’ (MPP) and pamidronate infusions (MPP 500 mg 3 consecutive days + pamidronate 60 mg in a slow IV infusion on day 2 of the MPP infusion). A minimum of six treatment cycles at monthly intervals were given. Adjunct treatment consisted of 1 gm elemental calcium supplementation, paracetamol 650 mg ‘as-and-when-required’ for symptomatic pain relief, amitriptyline 10 mg 2 hours before bed time daily.

Results: Of a total of 46 intent-to-treat patients, 39 patients achieved ASAS-20 and BASDAI-50 response (85%, 95% CI, range 71% to 94%); 7 (15 %) patients failed to improve. The expense involved in 6 months of treatment was approximately 10-fold less than anti-TNFα treatment over the same period of time.

Conclusion: For AS patients unresponsive to standard NSAIDs/coxibs and unable to take anti-TNF biological agents a combination therapeutic strategy showed efficacy and good tolerability in a majority of patients evaluated over a short-term.

INTRODUCTION

The mainstay of drug therapy in ankylosing spondylitis (AS) are nonsteroidal anti-inflammatory drugs (NSAIDs)/coxibs but, only about 50% of the patients get significant symptomatic relief in pain and stiffness over long-term.1 The advent of biological response modifiers (BRMs) namely anti-tumour necrosis factor-α (anti-TNFα) agents has improved the response rate so dramatically that in the latest international recommendations for AS treatment BRMs are recommended as the drug of choice for unresponsive patients.2 Unfortunately, for the patients in third world countries the exorbitant cost and serious threat of infectious complications, mainly reactivation tuberculosis, this promise has not been fulfilled.3,4 Therefore, there is a major therapeutic need to find alternatives to anti-TNFα BRMs for treating AS that are affordable and less likely to cause reactivation tuberculosis.

Using treatment paradigms for RA where combination-DMARDs with glucocorticoids have been shown to be more effective than DMARD monotherapy,5 Japanese workers have recently reported better efficacy of...
combination of MTX+SSZ than SSZ alone. In addition, there are recent reports of significant efficacy of pamidronate in AS. The present study took advantage of combining these 2 treatment modalities developing a more innovative treatment approach for AS patients. The regimen consisted of a combination of SSZ (daily) + MTX (weekly) combined with monthly infusions of MPP (X3 monthly) + pamidronate (single monthly dose synchronised with MPP).

MATERIAL AND METHODS

Patients: Patients were enrolled from the private clinic of one of the authors (ANM) or from among those attending the ‘Joint Disease Clinic’ at Indian spinal Injuries Centre Superspeciality Hospital (ISIC-SH), New Delhi. The diagnosis of AS was made according to modified New York criteria. The criteria for recruiting patients included 1. Definite diagnosis of AS. 2. Absence of peripheral arthritis. 3. Failure to get symptomatic relief (pain, stiffness, constitutional symptoms) despite at least 3 months of adequate doses of NSAIDs or coxibs. 4. Unable to take anti-TNFα agents (for various reasons, two mains ones being the expense and fear of developing active tuberculosis).

Treatment: After written consent and ethical clearance of the Hospital Ethics Committee selected patients were given the following treatment: (a) appropriate physiotherapy and occupational therapy advice; non-steroidal anti-inflammatory drugs (NSAIDs) or coxibs (on as-and-when-required basis for temporary pain relief) with adjunct supportive medicines including calcium (1 gm daily), vitamin D2 (minimum of 250 IU daily) and amitriptyline (10 mg daily 2 hours before going to bed); (b) SSZ (stepped up to 1 gm twice daily dose in 10 days) + MTX (subcutaneous injection stepped up from 10 mg to 20-25 mg weekly dose in a period of 4 weeks) along with adjunct therapy including folic acid supplementation (5 mg daily except on the day of MTX dose) (c) pamidronate monthly infusions given in the following schedule: MPP (500 mg intravenous ‘pulse’ infusion on 3 consecutive days, monthly) + pamidronate 60 mg in a slow IV infusion (single monthly dose on day 2 of the MPP ‘pulse’). A minimum of six treatment cycles at monthly intervals were given.

Disease assessment and data analysis: Disease was assessed using ‘instruments’ recommended by Assessment in AS (ASAS) working group namely: Bath ankylosing spondylitis disease activity score (BASDAI), Bath ankylosing spondylitis functional index (BASFI), Bath ankylosing spondylitis disease metrology index (BASMI), ASAS-recommended estimation of inflammation and erythrocyte sedimentation rate (ESR) (Appendix). Response was measured by comparing baseline values with values after completing 6th monthly cycle of treatment.

Improvement criteria: Improvement was defined

Appendix

CALCULATION OF BASDAI (Garrett S, et al. Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286- 91). (Scoring range 0-10) = (Mean score of the following 10 points)

Place a mark on each line below to indicate your answer to each question relating to the past 1 week.

1) How would you describe the overall level of fatigue / tiredness you have experienced?

0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10

NONE | | | | | | | | | | VERY SEVERE

2) How would you describe the overall level of neck, back or hip pain you have had?

0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10

NONE | | | | | | | | | | VERY SEVERE

3) How would you describe the overall level of pain / swelling in joints other than neck, back or hips you have had?

0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10

NONE | | | | | | | | | | VERY SEVERE

4) How would you describe the overall level of discomfort you have had from any areas tender to touch or pressure?

0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10

NONE | | | | | | | | | | VERY SEVERE

5) How would you describe the overall level of morning stiffness you have had from the time you wakeup?

0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10

NONE | | | | | | | | | | VERY SEVERE

6) How long your morning stiffness lasts from the time you wakeup?

or>

15 30 45 1 hr 1 1/2 hr 1 hr 2 hr

NONE | | | | | | | | | | VERY SEVERE

COMMENT: 50% improvement in BASDAI value from the base-line is considered ‘improvement’. This methodology has been popularly referred as ‘BASDAI-50’

CALCULATION OF BASFI (Calin A, et al. Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5): (Scoring range 0-10) = (Mean score of the following 10 points)

DRAW A MARK ON EACH LINE BELOW TO INDICATE YOUR LEVEL OF ABILITY WITH EACH OF THE FOLLOWING ACTIVITIES, DURING THE LAST 1 WEEK:

1) Putting your shoes / stockings without help:

EASY | | | | | | | | | | IMPOSSIBLE
according to ASAS criteria (called ASAS-20). (Appendix). In addition, 50% improvement in BASDAI was taken as another parameter to describe ‘BASDAI-50’ improvement (Appendix).

**RESULTS**

Demographic profile: The study included 46 ‘intent-to-treat’ patients. Details of patient characteristic are provided in Table 1. As can be seen, 63% of the patients had high disease activity with BASDAI ≥ 4 \(^{10}\) and ESR > 30 mm in the 1st hour at the baseline.

Analysis of results (Table 2): 39 of the 46 patients achieved ASAS-20 and BASDAI-50 improvement (85%; 95% CI, range 71% to 94%). Seven (15.2%) patients did not achieve ASAS-20 or BASDAI-50 response.

Comparative cost of the present treatment strategy versus anti-TNFα treatment: The total cost of 6 cycles of the therapy (including drugs, hospitalisation and related expenses) was approximately Rs. 40,000/- over 6 months. In comparison the cost of 5 doses of infliximab

---

**Assessments in ankylosing spondylitis (ASAS) working group criteria for response** [5]

<table>
<thead>
<tr>
<th>Improvement criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 20% and absolute improvement of ≥ 10 units</td>
<td>Patient global assessment, Pain, Function, Inflammation</td>
</tr>
<tr>
<td>≥ 3 domains worsening</td>
<td>Patient's global Assessment (Same as BASDAI point no. 1); Pain VAS (0-100); Function (Same as BASFI); Inflammation (0-100)</td>
</tr>
</tbody>
</table>

CAUTION: For scoring range 0-10 a centimetre scale is used; for scoring range 0-100 a millimetre scale is used. In effect it simply means that for all practical purposes a scale of 0-10 is used for final calculations.
of patients with AS that is effective and much more affordable for patients in developing countries. Considering that the over-all cost (including hospitalisations, drugs) was approximately 10-fold less than the internationally recommended anti-TNFα drug regimen, this treatment strategy could be a possible alternative for NSAID-unresponsive patients with AS in the third world countries.

The results showed that a majority of the patients unresponsive to NSAIDs achieved satisfactory response, with some of them showing dramatic improvement. The tolerability was excellent with only minor self-limiting adverse effects none of which required discontinuation of treatment.

It needs to be emphasised that this was not a comparative efficacy-assessing randomised controlled study with different intervention methods but only a strategy for treating NSAID-unresponsive patients. Also, despite efficacy of this combination-therapeutic strategy there are several shortcomings, problems and difficulties in its routine use. Firstly, it is cumbersome and expensive, as it requires monthly hospitalisation for IV infusions. Secondly, combining several drugs adds to the cost although it still remains much cheaper than anti-TNFα drugs. (Note: Pamidronate available in the Indian market is manufactured in India and its cost is several folds less than that in other countries).

Finally, long-term efficacy and safety of this therapeutic regimen remains unknown. Also, its comparison with 2-drug or 3-drug combinations or with TNF-α antibody, would require randomised control studies or in-practice cohort studies. Also, what happens to disease activity after six monthly IV infusion-cycles of methylprednisolone-pamidronate is discontinued, remains to be seen.

Acknowledgement

Authors would like to thank Dr. H. S. Chhabra, Addl. Medical Director, ISIC Superspeciality Hospital for help, co-operation, support and encouragement for carrying out this work. The help and co-operation of the nursing staff, other supporting staff and the administrative staff of the hospital is gratefully acknowledged. We also thank Renuka Saha, Associate Professor, Department of Preventive and Social Medicine, Maulana Azad Medical College, New Delhi for help in statistical analysis of the data. Meticulous computer data entry and data updating by Mr. Prashant Deshmukh and Miss Kiran Negi made it possible to analyse the results without any problem.

REFERENCES

2. Zochling J, van der Heijde, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systemic literature review for the ASAS/EULAR management

### Table 1: Demographic characteristics of 46 ‘intent-to-treat’ patients.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Median</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>28 years</td>
<td>18-47</td>
</tr>
<tr>
<td>Gender</td>
<td>Males: 39</td>
<td>Females: 7</td>
</tr>
<tr>
<td>Disease duration</td>
<td>5 years</td>
<td>1-15 years</td>
</tr>
<tr>
<td>BASDAI at baseline</td>
<td>BASDAI &gt; 4</td>
<td>29 (63%),</td>
</tr>
<tr>
<td>(severe disease*)</td>
<td>BASDAI from 3.9 to 2 (moderately severe disease)</td>
<td>12 (28.5%)</td>
</tr>
<tr>
<td>ESR at baseline (fasting)</td>
<td>ESR very high (≥ 100 mm 1st hour)</td>
<td>6 (15%)</td>
</tr>
<tr>
<td>Westergren</td>
<td>ESR high (50 to 99 mm 1st hour)</td>
<td>14 (34%)</td>
</tr>
<tr>
<td></td>
<td>ESR moderately high (30 to 49 1st hour)</td>
<td>13 (32%)</td>
</tr>
<tr>
<td></td>
<td>ESR normal (≥ 30 mm 1st hour)</td>
<td>8 (19%)</td>
</tr>
</tbody>
</table>

*Ref. 10

### Table 2: Forty-six ‘intent-to-treat’ patients with AS; 37 completed 6 months of treatment (9 drop-outs); results of ‘response’ as assessed by ASAS-20, B and ASDAI-50 improvement

<table>
<thead>
<tr>
<th>Parameter for measuring response</th>
<th>Number of patients who showed ‘response’</th>
<th>Percentage of ‘response’</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASAS-20</td>
<td>39</td>
<td>85 %</td>
</tr>
<tr>
<td>BASDAI-50</td>
<td>39</td>
<td>85 %</td>
</tr>
</tbody>
</table>

that would be required over a 6 month period (excluding the expense of hospitalisation) in a 70 kg man (needing 350 mg of the drug i.e. 4 vials @ of Rs. 36,000 per vial) would be Rs. 144,000/- × 3 = Rs. 432,000/-. For 6 months of etanercept (50 mg weekly @ of Rs. 17,000/-) the cost would be Rs. 102,000/-. It is obvious that the cost difference is ~ 10-fold.

**Tolerance and adverse effects:** In Four patients low grade fever (99-100 F) lasting less than 24 hrs. was noted after the first cycle of therapy. Five patients developed mild myalgias requiring paracetamol during first cycle of therapy. No abnormality in liver enzymes, renal parameters, haematological parameters were noted in any patient. One patient developed elevated blood glucose levels after the first cycle of therapy that was returned to normal range after 2 days of the last dose of intravenous methylprednisolone. In subsequent infusions, the period was covered with appropriate insulin dosages. No other adverse effects were noted. (Since the manuscript was submitted originally, now the follow-up has gone up to 1 year in several patients and no late adverse effects have been noted in them till now).

**DISCUSSION**

This study describes a novel strategy for treatment...

Book Review

Hematology Today 2007
Edited by Prof MB Agarwal

This is the new 2007 version of the state of the art masterpiece by Prof MB Agarwal, a clinician par excellence. It is a unique multiauthor compendium of the latest articles in hemato-oncology, which will useful not only to hematologist, pathologist but also to general physicians. It is a textbook with blend of academia and practitioners as well as international authorities across the globe which tell us the Best Practice situations of various disease states as well as novel technologies and treatments that are likely to be available in 2007. Each chapter has a succinct abstract, selected reading, illustration in colour and “Carry Home Message”. The sections are Anemia, Haemostatic and Thrombotic Disorders, Acute Leukemia and MDS, Chronic Leukemia, Lymphoma, Plasma Cell Dyscrasia, Transfusion Medicine and Transplantation, Support Therapy, Laboratory Science, etc. The whole book is hardbound and printed on quality art paper with colour illustrations. It can be an asset to any library both personal as well as that of academic institutions as collector’s classic of 2007.

Published by
Ashirwad Hematology Center
Vijay Sadan, Ground Floor, 168-B, Dr. B Ambedkar Road, Dadar T.T, Mumbai, India (On behalf of the XIIIth National CME in Haematology and Haematology-Oncology, Bombay Hospital Institute of Medical Sciences, Marine Lines, Mumbai – 400 020, India.
Tel: 91-22-22414227/224144453
Fax: 91-22-224140048
Email: mbagarwal@hotmail.com
Website: www.hemato-onco.com
Price Rs.2000/-